Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT

All India Institute Of Medical Science (AIIMS)

Status and phase

Completed

Phase 3

Conditions

Neurocysticercosis

Treatments

Drug: 28 days of albendazole 15 mg/kg/day

Drug: 7 days of albendazole 15 mg/kg/day

Study type

Interventional

Funder types

Other

Identifiers

NCT02243644

IESC/T-320/02.08.2013

Details and patient eligibility

About

Comparing the effect of two different duration of same drug albendazole in patients with Neurocysticercosis less than or equal to 5 lesions on CT head at the end of 6 months.

Full description

The trial will be comparing the effectiveness of short and long duration of albendazole ie 7 and 28 days therapy in patients with parenchymal neurocysticercosis in terms of complete resolution or calcification of cyst on CT head at the end of 6 months after starting albendazole

Enrollment

97 patients

Sex

All

Ages

2 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 2-18 years.
Number of parenchymal lesions: upto 5*
Stages of cysticerci at which albendazole treatment is effective
Vesicular stage
Colloid vesicular stage
Granular nodular stage

Exclusion criteria

Cysticercotic encephalitis
Calcified cyst
Hydrocephalus
Intraventricular cyst
Subarachnoid cyst
Ophthalmic Cysticercosis
No of cysts >5
Known allergy to benzimidazole class of compound which includes anaphylaxis, hypotension, severe skin reactions .
Features of raised ICT (papilloedema, hyperventilation, hypertension, tonic posturing, B/L 6th nerve palsy, features of midline shift on CT/MRI)
Critically sick (respiratory failure, cardiovascular instability)
Already received albendazole or praziquantel or steroid therapy